Market News & Trends
Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Lisata Therapeutics, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) to LSTA1, the company’s lead product candidate, for the treatment…
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
SciSparc Ltd. recently announced MitoCareX Bio Ltd., the company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics…
Bayer & Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines
Bayer AG and Thermo Fisher Scientific Inc. recently announced they will develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients…
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) From Roche
Lonza recently announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, CA, from Roche for….
Orchard Therapeutics Outlines US Launch Plans for the Only Approved Therapy for Children With Early Onset Metachromatic Leukodystrophy
Orchard Therapeutics recently announced the details of its US commercial launch of Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the….
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma, Inc. recently announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. “We are…
OKYO Pharma to Release New & Comprehensive Data GFrom Phase 2 Dry Eye Disease Trial
OKYO Pharma Limited recently announced it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on….
ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
ACELYRIN, INC. recently announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously….
RespireRx Pharmaceuticals Reports Preclinical Research Demonstrating the Ability of its Lead Clinical AMPAkine to Improve Bladder Function After Spinal Cord Injury
RespireRx Pharmaceuticals Inc. recently announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida…
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD & Stress-Induced Anxiety Therapeutic
Silo Pharma, Inc. recently announced it has exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from…
TFF Pharmaceuticals Announces Update on Clinical Programs
TFF Pharmaceuticals, Inc. recently announced data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of…
Petros Pharmaceuticals Successfully Launches AI Tool in Collaboration With Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals, Inc. recently announced it has successfully launched its artificial intelligence (AI) tool developed as a result of its collaboration with a multi-billion-dollar software developer.…
Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Ltd. recently announced the FDA advised the company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical…
Hovione & GEA Strengthen Partnership to Advance Continuous Tableting Technology
Hovione and GEA recently announced the next stage of their partnership, with new development agreements, the launch of the ConsiGma CDC flex as well as…
ReciBioPharm & GeneVentiv Therapeutics Partner to Advance First AAV-Based Gene Therapy for Haemophilia Patients With Inhibitors
ReciBioPharm has recently announced a collaboration agreement with GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for….
Anavex Life Sciences Initiates Placebo-Controlled US Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Anavex Life Sciences Corp. recently announced the first patient in its US FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX3-71 for the treatment of…
Sequel’s twiist Automated Insulin Delivery System Receives FDA 510(k) Clearance
Device bundles latest technology to deliver significant advancements for insulin management for people with type 1 diabetes….
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics, Inc. recently reported the European Patent Office (EPO) granted the company’s European Patent No. 3,562,486 on March 13, 2024. The 486 patent covers…
Curia Appoints Steve Lavezoli as Vice President, Biologics
Curia, a leading contract research, development and manufacturing organization, recently announced it has appointed Steve Lavezoli as Vice President of Biologics effective Feb. 26. Lavezoli…
Atrogi Announces Positive Clinical Data From First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Atrogi recently announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This…
